TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Geriatrician Nathaniel Chin says subjective cognitive decline can merit closer evaluation even when comprehensive testing shows no objective impairment. He describes baseline and repeat testing, checks for other causes, and selective use of Alzheimer’s biomarkers as possible steps; subjective decline alone does not establish Alzheimer’s disease.
Geriatrician Nathaniel Chin says people who report persistent changes in memory or thinking may need more than reassurance when testing remains within the normal range. In a physician commentary published by Being Patient on October 27, 2026, he describes subjective cognitive decline as a reason to establish a detailed baseline, consider other causes and follow changes over time—not as proof that a person has Alzheimer’s disease.
Subjective cognitive decline (SCD) refers to a person’s continuing sense that their cognitive abilities have worsened compared with their own earlier level, even though comprehensive testing does not identify objective impairment. Chin says a normal score can miss a meaningful personal change, especially when someone’s previous abilities were higher than average. Testing often compares a person with others of similar age rather than measuring them against their own earlier performance.
He distinguishes a brief screening test, which may take five to 15 minutes, from a comprehensive cognitive evaluation, which can take an hour or more and assess areas such as memory, language, attention and planning. In his view, a sufficiently thorough evaluation is needed before describing a person’s experience as SCD, and repeated testing can help show whether abilities remain stable or decline over time.
Chin also lists possible contributors beyond Alzheimer’s, including sleep problems, medications, depression or anxiety, medical illness, vascular disease, hearing loss, stress and normal aging. He recommends considering these factors rather than treating the symptom label as an explanation. For some selected patients, he says, blood tests for Alzheimer’s-related biomarkers, cerebrospinal fluid testing or amyloid PET imaging may help assess whether biological changes associated with the disease are present. The supplied article excerpt does not specify which patients should receive those tests or provide results from a new study.
Why Normal Scores May Miss Change
Chin’s central point is that a normal test result is not the same as proof that nothing has changed. A person may notice persistent difficulties in everyday life before performance falls below a threshold used to identify impairment. Recognizing that distinction could prompt clinicians and patients to document symptoms and monitor them, rather than waiting for a later decline to become measurable.
The approach also matters because Alzheimer’s disease is only one possible explanation. A careful evaluation can look for other factors that may affect cognition, some of which may be addressed through medical care. Chin’s commentary presents earlier assessment as a way to make follow-up more informative and consider testing when appropriate; it does not establish that early testing prevents Alzheimer’s or that every person reporting forgetfulness needs biomarker tests.
Products Worth Considering
Weber Genesis E-415 4-Burner Propane Gas Grill, Black
Traeger Woodridge Pro Wood Pellet Grill and Smoker, 970 sq. in., WiFIRE
Weber Searwood 600 Wood Pellet Smoker Grill, Black
As an affiliate, we earn on qualifying purchases.
How Clinicians Describe SCD
Chin’s commentary draws on the concept of “SCD plus,” developed by psychiatrist Frank Jessen and colleagues in the international Subjective Cognitive Decline Initiative. The listed features that may make subjective decline more concerning include memory-focused complaints, onset within the past five years and at age 60 or older, worry about the change, persistence, seeking medical help and confirmation by someone who knows the person well.
These features are not diagnostic criteria proving Alzheimer’s. Chin says that several appearing together may warrant closer attention. He contrasts a long-running, intermittent concern associated with poor sleep or stress with a more recent, persistent memory change in an older adult that is also noticed by a spouse. Both people could score in the normal range, but the pattern and supporting observations would lead him to approach them differently.
What SCD Cannot Establish
SCD does not identify the cause of a person’s concern and does not, by itself, confirm Alzheimer’s disease. The features in the SCD-plus framework are described as reasons for closer attention, not proof that disease is present. The commentary also names several non-Alzheimer’s contributors, so an individual assessment is needed to interpret symptoms.
The available source excerpt ends as Chin begins discussing biomarkers. It does not give the full discussion, details about test accuracy, eligibility or costs, or evidence that using biomarkers in people with SCD prevents disease or improves outcomes. It also provides no new clinical trial findings or population-level estimates of how often SCD progresses to impairment.
How Follow-Up May Proceed
For a person with persistent concerns, Chin describes a practical sequence: take a detailed history, arrange a thorough cognitive baseline, review possible contributing factors, and—with the person’s agreement—ask someone familiar with their day-to-day functioning about observed changes. Repeat evaluations can then help establish whether the pattern is stable or changing.
For selected patients, clinicians may discuss blood biomarkers, cerebrospinal fluid testing or amyloid PET to examine Alzheimer’s-related biology. The commentary does not set a schedule for repeat testing or define who should undergo biomarker assessment. The next step for any individual depends on clinical evaluation; a subjective complaint or this article alone cannot provide a diagnosis.
Key Questions
What is subjective cognitive decline?
SCD is a persistent sense that memory or another cognitive ability has declined from a person’s earlier level, despite comprehensive testing that does not show objective impairment. It describes the reported change, not its cause.
Does subjective cognitive decline mean someone has Alzheimer’s?
No. Chin says SCD does not mean Alzheimer’s disease. Sleep, mood, medications, illness, hearing loss, vascular disease, stress and normal aging can also affect how thinking feels.
Why might a normal cognitive test not settle the concern?
A score may be compared with other people of similar age rather than with the individual’s earlier abilities. A short screening test also checks fewer areas than a comprehensive evaluation; repeat testing can help track change.
What does the SCD-plus framework indicate?
It lists features—such as recent, persistent memory concerns, worry, older age at onset and confirmation by someone close—that may make a complaint more deserving of follow-up. The features do not prove Alzheimer’s is present.
Can biomarkers detect Alzheimer’s before impairment?
Chin says blood biomarkers, cerebrospinal fluid testing and amyloid PET may help determine whether Alzheimer’s-related biological changes are present in selected patients. The supplied article excerpt does not provide test-selection guidance or show that testing prevents disease.
Source: rss
